The global clinical trials activity saw an increase of 1.2% in Q3 2020, when compared with the rolling average of the last four quarters (Q3 2019 to Q2 2020), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 51.5% share in Q3 2020, marking an increase of 5.8% in the total share when compared with the four-quarter average.
Non-industry sponsored trials accounted for a 48.5% share of all the clinical trials globally in Q3 2020, marking a decrease of 5.8% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q3 2020
Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2020, accounting for a 27.8% share of all trials.
This was followed by the following therapy areas: Infectious Disease with a 20.6% share, Central Nervous System with a 12.9% share, Respiratory with a 7.4% share and Gastrointestinal with a 6.9% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.2% share, followed by Infectious Disease with a 16.4% share, Central Nervous System with a 13.7% share, Respiratory with an 8.4% share, and Metabolic Disorders with an 8.1% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2020 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2020 | Activity |
| Oncology | 27.2% | 27.8% |  |
| Infectious Disease | 16.4% | 20.6% | |
| Central Nervous System | 13.7% | 12.9% |  |
| Respiratory | 8.4% | 7.4% | |
| Gastrointestinal | 7.0% | 6.9% | |
| Metabolic Disorders | 8.1% | 6.9% | |
| Cardiovascular | 7.7% | 6.7% | |
| Dermatology | 4.7% | 4.3% | |
| Immunology | 5.4% | 4.3% | |
| Musculoskeletal Disorders | 3.8% | 3.5% | |
| Ophthalmology | 2.8% | 3.0% | |
| Hematological Disorders | 2.8% | 2.7% | |
| Genito Urinary System And Sex Hormones | 2.8% | 2.4% | |
| Genetic Disorders | 1.5% | 2.0% | |
| Women’s Health | 2.1% | 1.6% | |
| Ear Nose Throat Disorders | 1.6% | 1.1% | |
| Male Health | 0.9% | 0.7% | |
| Hormonal Disorders | 0.5% | 0.4% | |
| Mouth and Dental Disorders | 0.7% | 0.4% | |
| Nutritional Disorders | 0.5% | 0.2% | |
| Non Malignant Disorders | 0.2% | 0.1% | |
Oncology was the leading therapy area for non-industry-sponsored clinical trials in Q3 2020, accounting for a 24.9% share of all trials.
This was followed by the following therapy areas: Infectious Disease with a 22.4% share, Central Nervous System with a 20.4% share, Cardiovascular with an 8.0% share, and Respiratory with a 6.2% share.
In the last four quarters, Central Nervous System held a lead over others for non-industry sponsored clinical trials with an average share of 22.4%, followed by Oncology with a 19.9% share, Infectious Disease with an 18.0% share, Cardiovascular with an 8.3% share, and Respiratory with an 8.0% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2020 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2020 | Activity |
| Oncology | 19.9% | 24.9% | |
| Infectious Disease | 18.0% | 22.4% | |
| Central Nervous System | 22.4% | 20.4% | |
| Cardiovascular | 8.3% | 8.0% | |
| Respiratory | 8.0% | 6.2% | |
| Gastrointestinal | 6.6% | 5.0% | |
| Women’s Health | 5.0% | 4.4% | |
| Metabolic Disorders | 5.8% | 4.1% | |
| Musculoskeletal Disorders | 5.1% | 4.1% | |
| Hematological Disorders | 2.9% | 3.4% | |
| Immunology | 3.3% | 3.1% | |
| Genito Urinary System And Sex Hormones | 3.3% | 2.9% | |
| Dermatology | 3.3% | 2.3% | |
| Mouth and Dental Disorders | 2.3% | 1.9% | |
| Ophthalmology | 1.8% | 1.2% | |
| Nutritional Disorders | 0.7% | 0.9% | |
| Ear Nose Throat Disorders | 1.3% | 0.8% | |
| Genetic Disorders | 0.6% | 0.6% | |
| Hormonal Disorders | 0.7% | 0.6% | |
| Male Health | 0.7% | 0.5% | |
| Non Malignant Disorders | 0.4% | 0.4% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q3 2020
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q3 2020 with a 47.2% share, compared to 53.0% in the last four quarters.
North America stood at second place with a 38.2% share in Q3 2020, over 31.6% in the last four quarters, followed by Europe with a 29.5% share in Q3 2020, as against 28.4% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 82.8% share in industry sponsored clinical trials in Q3 2020 when compared with 84.5% of average recorded in the last four quarters. Multinational trials accounted for a 17.2% share in Q3 2020, as against the four-quarter average of 15.5%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q3 2020 with a 42.8% share, over 49.4% in the last four quarters.
North America held the second position with a 24.8% share in Q3 2020, over 16.7% in the last four quarters, followed by Middle East and Africa with a 16.1% share in Q3 2020, as against 18.4% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.5% share for non-industry sponsored clinical trials in Q3 2020, compared to 98.8% in the last four quarters. Multinational trials accounted for a 1.5% share in Q3 2020, as against 1.2% in the last four quarters.
Industry and industry sponsored clinical trials by Phase in Q3 2020
Phase II trials outnumbered all other studies with a 37.1% share for industry sponsored trials in Q3 2020, compared to 34.5% average in the last four quarters.
The share of Phase I trials stood at 34.0% in Q3 2020, as against the four-quarter average of 36.3%. Phase III trials held a 16.9% share in Q3 2020, remaining flat over the last four quarters average, followed by Phase IV trials with an 11.9% share in Q3 2020, as against the four-quarter average of 12.3%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 47.0% share for non-industry sponsored clinical trials in Q3 2020, compared to 42.9% in the last four quarters.
Phase III trials stood at second place with a 19.1% share in Q3 2020, compared to 20.8% in the last four quarters. Phase IV trials held a 17.9% share in Q3 2020, as against 19.8% in the last four quarters, followed by Phase I trials with a 16.0% share in Q3 2020 over 16.6% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.